Browse

+AA

View All Topics

Liver conditions

Get the latest content first. Sign up for free weekly email alerts.

Filter Results

6 Show All 0Blog Posts 1Evidence Summaries

Want to know what professionals are reading?

Search all our content.

Browse other AGE-WELL categories

Supportive homes and communities Health care and health service delivery Autonomy and independence Cognitive health and dementia Mobility and transportation Healthy lifestyles and wellness Staying connected Financial wellness and employment

Evidence Summary

In people who have hepatitis C type 1, adding telaprevir, boceprevir, simeprevir, or sofosbuvir to usual treatment may improve response to treatment and increase side-effects
JAMA (2014)

Want the latest in aging research? Sign up for our email alerts.

Our Content

About

Support for the Portal is largely provided by the Labarge Optimal Aging Initiative. AGE-WELL is a contributing partner. Help us to continue to provide direct and easy access to evidence-based information on health and social conditions to help you stay healthy, active and engaged as you grow older. Donate Today.

Liver conditions

Want to know what professionals are reading?

Browse other AGE-WELL categories

In people who have hepatitis C type 1, adding telaprevir, boceprevir, simeprevir, or sofosbuvir to usual treatment may improve response to treatment and increase side-effects

Our Content

About